JPWO2021032851A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021032851A5 JPWO2021032851A5 JP2022510801A JP2022510801A JPWO2021032851A5 JP WO2021032851 A5 JPWO2021032851 A5 JP WO2021032851A5 JP 2022510801 A JP2022510801 A JP 2022510801A JP 2022510801 A JP2022510801 A JP 2022510801A JP WO2021032851 A5 JPWO2021032851 A5 JP WO2021032851A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- induction medium
- population
- mesoderm
- progenitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 80
- 230000006698 induction Effects 0.000 claims description 37
- 230000004069 differentiation Effects 0.000 claims description 29
- 210000003716 mesoderm Anatomy 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 15
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 15
- 210000001978 pro-t lymphocyte Anatomy 0.000 claims description 14
- 108010059616 Activins Proteins 0.000 claims description 12
- 239000000488 activin Substances 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 11
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 11
- 210000001704 mesoblast Anatomy 0.000 claims description 11
- 230000003394 haemopoietic effect Effects 0.000 claims description 10
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 10
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 102000003951 Erythropoietin Human genes 0.000 claims description 8
- 108090000394 Erythropoietin Proteins 0.000 claims description 8
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 8
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 8
- 108090000031 Hedgehog Proteins Proteins 0.000 claims description 8
- 102000003693 Hedgehog Proteins Human genes 0.000 claims description 8
- 108010033276 Peptide Fragments Proteins 0.000 claims description 8
- 102000007079 Peptide Fragments Human genes 0.000 claims description 8
- 102000036693 Thrombopoietin Human genes 0.000 claims description 8
- 108010041111 Thrombopoietin Proteins 0.000 claims description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229940105423 erythropoietin Drugs 0.000 claims description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 8
- 108010083359 Antigen Receptors Proteins 0.000 claims description 7
- 102000006306 Antigen Receptors Human genes 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 claims description 5
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 4
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 102000001267 GSK3 Human genes 0.000 claims description 4
- 108060006662 GSK3 Proteins 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 108090000177 Interleukin-11 Proteins 0.000 claims description 4
- 108010002386 Interleukin-3 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 102100020880 Kit ligand Human genes 0.000 claims description 4
- 101710177504 Kit ligand Proteins 0.000 claims description 4
- 229950006323 angiotensin ii Drugs 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 238000010362 genome editing Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 102000050057 Goosecoid Human genes 0.000 claims description 2
- 108700031316 Goosecoid Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 claims description 2
- -1 Mixll Proteins 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100021382 Transcription factor GATA-6 Human genes 0.000 claims description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000011748 cell maturation Effects 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 102000005606 Activins Human genes 0.000 claims 6
- 101150021185 FGF gene Proteins 0.000 claims 3
- 102000010913 Type 1 Angiotensin Receptor Human genes 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 13
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 11
- 229940126864 fibroblast growth factor Drugs 0.000 description 11
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 6
- 102100026818 Inhibin beta E chain Human genes 0.000 description 6
- 102100026803 Type-1 angiotensin II receptor Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 3
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 3
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 3
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 3
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 3
- 102100030607 Mothers against decapentaplegic homolog 9 Human genes 0.000 description 3
- 101700032040 SMAD1 Proteins 0.000 description 3
- 101700031501 SMAD9 Proteins 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000690425 Homo sapiens Type-1 angiotensin II receptor Proteins 0.000 description 1
- 101000890951 Homo sapiens Type-2 angiotensin II receptor Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000008410 smoothened signaling pathway Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1911957.7 | 2019-08-20 | ||
| GBGB1911957.7A GB201911957D0 (en) | 2019-08-20 | 2019-08-20 | Methods of producing haemogenic progenitor cells from pluripotent stem cells |
| PCT/EP2020/073396 WO2021032851A1 (en) | 2019-08-20 | 2020-08-20 | Methods of producing haemogenic progenitor cells from pluripotent stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545782A JP2022545782A (ja) | 2022-10-31 |
| JPWO2021032851A5 true JPWO2021032851A5 (https=) | 2023-08-18 |
| JP2022545782A5 JP2022545782A5 (https=) | 2023-08-18 |
Family
ID=68099409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510801A Pending JP2022545782A (ja) | 2019-08-20 | 2020-08-20 | 多能性幹細胞から造血性前駆細胞を生産する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220267733A1 (https=) |
| EP (1) | EP4017967A1 (https=) |
| JP (1) | JP2022545782A (https=) |
| KR (1) | KR20220049032A (https=) |
| CN (1) | CN114269906A (https=) |
| AU (1) | AU2020332863A1 (https=) |
| BR (1) | BR112022003089A2 (https=) |
| CA (1) | CA3150427A1 (https=) |
| GB (1) | GB201911957D0 (https=) |
| IL (1) | IL290605A (https=) |
| MX (1) | MX2022001960A (https=) |
| WO (1) | WO2021032851A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| GB202102297D0 (en) * | 2021-02-18 | 2021-04-07 | Adaptimmune Ltd | Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells |
| CN113046318B (zh) * | 2021-04-13 | 2023-04-18 | 中国科学院深圳先进技术研究院 | 一种诱导多能干细胞向造血前体细胞分化的培养基以及方法 |
| EP4326852A4 (en) * | 2021-04-22 | 2025-04-23 | Artec Biotech, Inc. | Method for producing hematopoietic cells from stem cells using vascular organoids |
| CN113265377B (zh) * | 2021-06-11 | 2023-01-24 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 一种动脉内皮促进功能性t细胞再生的方法 |
| JP2024531626A (ja) * | 2021-09-10 | 2024-08-29 | スンクワン メディカル ファウンデーション | 分化全能性幹細胞由来の造血幹細胞の製造方法、及び製造された造血幹細胞を利用したヒト化マウスモデル作製方法 |
| CN116410927A (zh) * | 2021-12-31 | 2023-07-11 | 士泽生物医药（苏州）有限公司 | 干细胞诱导分化为造血祖细胞的方法 |
| CN116376822A (zh) * | 2021-12-31 | 2023-07-04 | 北京大学 | 利用人多潜能干细胞体外制备t淋巴细胞 |
| TW202340453A (zh) * | 2022-01-28 | 2023-10-16 | 中國大陸商杭州啟函生物科技有限公司 | 用於基於細胞的免疫療法的方法和組合物 |
| GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| GB202208545D0 (en) | 2022-06-10 | 2022-07-27 | Adaptimmune Ltd | Production of immune cells |
| CN114958771B (zh) * | 2022-06-27 | 2023-12-05 | 广东康盾创新产业集团股份公司 | 一种ipsc-car-nk细胞的制备方法 |
| CN115247151B (zh) * | 2022-09-21 | 2022-12-27 | 呈诺再生医学科技(北京)有限公司 | 制备造血内皮细胞的方法及制备造血干细胞或造血干祖细胞的方法 |
| KR20240054468A (ko) * | 2022-10-18 | 2024-04-26 | 의료법인 성광의료재단 | 줄기세포에서 대식세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법 |
| US20240316196A1 (en) * | 2022-12-02 | 2024-09-26 | Nuwacell Biotechnologies Co., Ltd. | Methods and compositions for differentiation of pluripotent stem cells and derived natural killer cells |
| CN117264888A (zh) * | 2023-10-11 | 2023-12-22 | 苏州艾凯利元生物科技有限公司 | 一种制备造血干细胞和祖细胞的方法 |
| GB202318950D0 (en) | 2023-12-12 | 2024-01-24 | Adaptimmune Ltd | Production of immune cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008151390A1 (en) * | 2007-06-15 | 2008-12-18 | Australian Stem Cell Centre Ltd | Differentiation of human embryonic stem cells |
| JP5777115B2 (ja) * | 2010-03-18 | 2015-09-09 | 国立大学法人京都大学 | 多能性幹細胞から中胚葉細胞への分化誘導法 |
| JP6677631B2 (ja) * | 2013-03-13 | 2020-04-08 | ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 定義された条件下におけるヒト多能性幹細胞の造血内皮分化のための方法及び材料 |
| CA2925774A1 (en) * | 2013-10-01 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human ipsc-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings |
| AU2016211671B2 (en) * | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2975268A1 (en) * | 2015-02-20 | 2016-08-25 | Wisconsin Alumni Research Foundation | Generating arterial endothelial cell populations |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3003152A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| US11261430B2 (en) * | 2016-05-03 | 2022-03-01 | The Children's Medical Center Corporation | Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells |
| EP3621630A4 (en) * | 2017-06-14 | 2021-03-10 | The Children's Medical Center | HEMATOPOIETIC STEM AND PRECURSOR CELLS FROM HEMOGENIC ENDOTHELIAL CELLS BY EPISOMAL PLASMID GENERAL TRANSFER |
| SG11202006731VA (en) * | 2018-01-18 | 2020-08-28 | Agency Science Tech & Res | Method for differentiation of human pluripotent stem cell lines in suspension culture |
| GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
-
2019
- 2019-08-20 GB GBGB1911957.7A patent/GB201911957D0/en not_active Ceased
-
2020
- 2020-08-20 MX MX2022001960A patent/MX2022001960A/es unknown
- 2020-08-20 CN CN202080059222.4A patent/CN114269906A/zh active Pending
- 2020-08-20 AU AU2020332863A patent/AU2020332863A1/en not_active Abandoned
- 2020-08-20 JP JP2022510801A patent/JP2022545782A/ja active Pending
- 2020-08-20 EP EP20761193.0A patent/EP4017967A1/en active Pending
- 2020-08-20 BR BR112022003089A patent/BR112022003089A2/pt unknown
- 2020-08-20 CA CA3150427A patent/CA3150427A1/en active Pending
- 2020-08-20 WO PCT/EP2020/073396 patent/WO2021032851A1/en not_active Ceased
- 2020-08-20 KR KR1020227009012A patent/KR20220049032A/ko active Pending
- 2020-08-20 US US17/630,882 patent/US20220267733A1/en active Pending
-
2022
- 2022-02-14 IL IL290605A patent/IL290605A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021032851A5 (https=) | ||
| JP6800859B2 (ja) | 造血細胞分化を誘導するための方法および組成物 | |
| US9771561B2 (en) | Method of making primate cells expressing apelin receptor that have mesangioblast potential | |
| CN103003416B (zh) | 从小体积的外周血产生诱导性多潜能干细胞 | |
| Lupo et al. | Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum-and feeder-free conditions | |
| CN114341349A (zh) | 造血诱导培养基 | |
| KR20190018709A (ko) | 혈액을 유도 만능 줄기세포로 리프로그래밍하기 위한 신규하고 효율적인 방법 | |
| WO2013075222A1 (en) | Populations of hematopoietic progenitors and methods of enriching stem cells therefor | |
| CN104774809A (zh) | 血管瘤集落形成细胞和非移植血管瘤细胞 | |
| IL305018A (en) | Methods of producing haemogenic endothelial cells from pluripotent stem cells | |
| JPWO2021032855A5 (https=) | ||
| CN116376822A (zh) | 利用人多潜能干细胞体外制备t淋巴细胞 | |
| Galić et al. | Generation of T lineage cells from human embryonic stem cells in a feeder free system | |
| Philonenko et al. | Recapitulative haematopoietic development of human pluripotent stem cells in the absence of exogenous haematopoietic cytokines | |
| Lee et al. | Forced expression of HoxB4 enhances hematopoietic differentiation by human embryonic stem cells | |
| Gong et al. | Interplay of transcription factors and microRNAs during embryonic hematopoiesis | |
| CN108642083A (zh) | 一种将t细胞高效诱导成多能干细胞的重编程方法 | |
| CN115087732B (zh) | 来自人T细胞来源的iPS细胞的细胞毒性T细胞 | |
| JPWO2022175401A5 (https=) | ||
| JPWO2021032852A5 (https=) | ||
| Wang | Endothelial and hematopoietic cell fate of human embryonic stem cells | |
| Zhang et al. | PEAR1 is a potential regulator of early hematopoiesis of human pluripotent stem cells | |
| WO2023233339A1 (en) | Compositions and methods for differentiating stem cells into nk cells | |
| KR20240169086A (ko) | 난원세포-유사 세포를 생산하는 방법 및 조성물 | |
| RU2022107099A (ru) | Культуральная среда для гемопоэтической индукции |